InvestorsHub Logo
Followers 22
Posts 747
Boards Moderated 0
Alias Born 09/07/2016

Re: ralphey post# 115408

Tuesday, 10/03/2017 4:41:56 PM

Tuesday, October 03, 2017 4:41:56 PM

Post# of 426454
Ralphey - Have you heard of cost/benefit analysis, number needed to treat etc.? Believe me insures care about cost effectiveness- as we all should as docs. So, yes medical organizations determine things like Quality Adjusted Life Years (usually around $50,000) to see if something is cost effective. Yes, then insurers will look at what is most cost effective to steer providers and patients towards that treatment.
So, the reason your $12K drug is likely to get denied is because it is not cost effective in the population you selected or there may be a better alternative.
Sure, I'm not naive enough to deny that insurers want to make money but we already spend 3x as much money per person than most other countries. We need some criteria to use in selecting treatments that don't brake the bank and Vascepa hopefully will be one of those- and yes insurers will pay for it if it works.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News